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 With previous indication of the Group VIA phospholipase A2 (iPLA2β) enzyme 
regulating ER-stress induced apoptosis in β-cells by regulating the anti-apoptotic protein 
Bcl-xL via alternative splicing, our lab postulated iPLA2β to be utilizing a similar 
mechanism to regulate apoptosis in mice lung. Our previous lab work has shown 
implications of lung function compromise in iPLA2β-/- mice, and we speculated the cause 
to be due altered lung architecture stemming from the attenuation of apoptosis. The 
western blot analysis in this study suggested that iPLA2β is involved in the regulation of 
Bcl-xL, but the mRNA ratios of the splice variants suggested that alternative splicing is 
not the mechanism iPLA2β is utilizing for the regulation in our animal models. 
Additionally, the observation and assessment of the lung morphology of the iPLA2β-/-
  
  
 and wild type mice suggested that iPLA2β does not play an integral role in lung 
morphology.
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Introduction 
 
 
 
In multicellular organisms, part of survival is ironically dependent on death. 
Apoptosis, also known as programmed cell death, is a physiological process that occurs 
normally in multicellular organisms to maintain a balance in cellular proliferations by 
having an impact on a variety of biological events. These events range from 
embryogenesis and cellular homeostasis to disposal of harmful and damaged cells [1]. 
The term “apoptosis” was first used by John Kerr and colleagues in the early 1970’s to 
refer to the features of the unique morphological observation of cell death [2].  
Some of the characteristics of cells going through apoptosis are loss of cellular 
contact with the matrix, nuclei condensation, plasma-membrane blebbing, cellular 
shrinkage, DNA fragmentation and disintegration of mitochondria [1]. Due to apoptosis 
having an integral role in many important biological events, abnormalities in the pathway 
of apoptosis can lead to various pathological conditions such as cancer, cardiovascular 
disease, autoimmune and neuronal disorders [3]. 
Apoptosis is triggered and regulated by a wide variety of factors and has 
conserved genetic and biochemical pathways as it is an important part of maintenance 
of homeostatic balance [4]. Some of the factors that induce apoptosis are death 
receptor ligands, such as Fas-ligands and tumor necrosis factor (TNF) [5]. Ultraviolet 
irradiation, bacteria, DNA damage, oxidative stress and ceramide treatment can also 
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trigger apoptosis, while various growth factors can regulate the process [6].  Apoptotic 
stimuli can lead to two pathways of apoptosis, which are the extrinsic pathway, also 
known as the death receptor pathway, and the intrinsic pathway, also known as the 
mitochondrial pathway [7]. A group of apoptosis regulating proteins, Bcl-2 related 
protein family, mediates the intrinsic pathway, while extracellular signals from other cells 
activate the extrinsic pathway [4].  
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Bcl-2 family 
 
 
 
Evidence of physiological cell death tied to genetics was first observed in 
developmental studies in the 1980’s of the invertebrate organism, C. elegans. Genetic 
studies lead to the discovery of genes necessary for regulation, execution and 
resolution of apoptosis during the development stages of C. elegans such as egl-1, ced-
3, ced-4 and ced-9. Proteins derived from egl-1, ced-3 and ced-4 caused programmed 
cell death, while the anti-apoptotic ced-9 protein prevented death of the cells destined to 
die during the developmental stages of C. elegans. Studies on the mechanism of 
programmed cell death flourished and mammalian homologue genes were discovered 
with the discovery of these genes. One of the key regulator proteins of apoptosis, Bcl-2 
protein, was discovered soon after as the mammalian homologue of Ced-9 [8].  
First observed in B-cell lymphomas of humans [9], the B-cell 
lymphoma/leukemia-2 (bcl-2) gene’s anti-apoptotic effects demonstrated the correlation 
between the regulation of cell death and the development of tumors [10]. Over 
expression of Bcl-2 in cytokine dependent cell lines inhibited cell death caused by 
growth factor deprivation [6]. However, the promotion of cell proliferation was not 
observed in these cells suggesting that cell death and cytokine stimulated cell 
proliferation did not share a same mechanism [6]. These results suggested that cell 
death is regulated by a molecular mechanism separate from the mechanism of cytokine 
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stimulated cell proliferation, and for the first time demonstrated that abnormalities in the 
regulation of cell death could lead to cancer development [6].  
With the discovery of Bcl-2, the importance of the regulation of apoptosis was 
demonstrated, which opened new doors and insight to cancer biology. The intense 
studies in this field lead to discoveries of many different Bcl-2 related proteins [6]. These 
apoptosis regulating proteins were soon categorized into one pro-survival subgroup and 
two pro-apoptotic subgroups [11]. It is the interactions of these three subgroups of the 
Bcl-2 related proteins on the mitochondrial outer membrane that subsequently regulate 
apoptosis. Due to the utilization of the three functionally and structurally distinct 
subgroups, the Bcl-2 protein family can be regarded as a tripartite apoptotic switch [12].  
The factor that ties the members of the Bcl-2 related proteins into one family is the 
conserved BH, short for Bcl-2 homology, domains they possess. There are four distinct 
BH domains which correspond to the alpha-helical segments of the proteins and all 
subgroups possess the BH3 domain [13]. The protein members of the pro survival/anti 
apoptotic subgroup and the multi-domain effector proteins of the pro apoptotic subgroup 
possess all four BH domains and form globular structures. These structures are formed 
by surrounding one central hydrophobic core helix with a bundle of α helices, which 
produce hydrophobic surface grooves generated by the folding of helices. The tertiary 
structure provides the functionality of the proteins by allowing these grooves to be used 
as vital interfaces for the interaction with the BH3 domain of pro-apoptotic members 
[12].  
Having their N-terminus face the cytosol, Bcl-2 related proteins carry their 
hydrophobic membrane insertion domain on their C-terminus. The membrane insertion 
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domain allows the proteins to integrate into the cytosolic side of the mitochondrial 
membrane, endoplasmic reticulum and nuclear envelope. The orientation of the proteins 
facing the cytosol allows the protein to interact with their associated proteins to function. 
The localization of the Bcl-2 related proteins can vary [13]. The variance of localization 
of the Bcl-2 related proteins can be due to their functions. For example, there are 
indications of BAX, an apoptotic Bcl-2 related protein, traveling back and forth from the 
cytosol to the outer mitochondrial membrane in healthy cells. They are suggested to be 
retro-translocated to the cytosol by Bcl-xL and other pro-survival Bcl-2 related proteins 
to prevent the accumulation of BAX thus preventing apoptosis [14]. 
 
Pro-apoptotic initiators 
(BH3-only) 
Pro-apoptotic mediators 
(Multi-domain) 
Anti-apoptotic/Pro-
survival  
Bik, Bad, Bid, Bim, Bmf, 
Hrk, Noxa, Puma, tBID 
Bak, Bax, Bok A1, Bcl-2, Bcl-B, Bcl-W, 
Bcl-xL, Mcl-1 
 
Figure 1. Bcl-2 related protein family 
 
The pro-apoptotic subgroups of Bcl-2 related proteins consists of the BH3-only 
proteins and the multi-domain pro-apoptotic proteins.  Currently the BH3-only protein 
subgroup is consisted of members including Bik, Bad, Bid, Bim, Bmf, Hrk, Noxa, Puma 
and tBID, and the multi-domain pro-apoptotic protein subgroup members are composed 
of Bak, Bax and Bok [15].  
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Unlike the previously mentioned multi domain proteins, BH3-only proteins 
possess one BH domain. Once activated by a cytotoxic signal, the BH3-only proteins 
carry out their function by forming a complex with the pro-survival proteins by the 
formation of a salt bridge between the conserved Asp residue and the conserved Arg 
residue located in the BH1 domain of the pro-survival proteins [16]. While the BH3-only 
proteins can carry out apoptotic function by neutralizing the pro-survival proteins, there 
are also suggestions for a direct activation of the multi domain pro-apoptotic proteins by 
these proteins [17]. Regardless of the mechanism of the protein, the subsequent effect 
is the homo-oligomerization of the multi-domain pro-apoptotic proteins, BAK and BAX, 
which leads to formation of pores in the outer mitochondrial membrane [18]. The pores 
increase the permeability of the outer mitochondrial membrane leading to the release of 
Smac and cytochrome c into the cytosol, which induces a series of cascades leading to 
apoptosis [19].  
The pro-survival Bcl-2 related proteins, consists of members including A1, Bcl-2, 
Bcl-B, Bcl-W, Bcl-xL and Mcl-1. These proteins are antagonists of the BH3-only proteins 
that prevents the effects of various cytotoxic stimuli by neutralizing the apoptotic BH3-
only proteins or by directly binding to the BH3 domain of activated BAK and BAX to 
inhibit their pro-apoptotic function [20]. The competition between the BH3-only proteins 
and the pro-survival proteins to regulate the multi domain pro-apoptotic proteins, BAK 
and BAX, suggests that the relative ratio of the two proteins dictate the sensitivity or 
resistance of the cell to apoptotic stimuli [21].  
Alternative splicing of pre-mRNA is a common method of genes to encode for 
different variants of proteins having different functions. This method is utilized by the 
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Bcl-x pre-mRNA to produce two distinct isoforms, Bcl-xL and Bcl-xS [22]. Our target 
protein Bcl-xL is a longer isoform, 241 amino acid long in length, containing an internal 
region of 63 amino acids that shows the greatest homology to Bcl-2. This internal region 
is deleted in the shorter isoform Bcl-xS, which is 178 amino acid long, and shows to be 
the reason for Bcl-xS to not have the same function as Bcl-xL [18][23]. Functionally Bcl-
xL prevents cell death, but Bcl-xS’s role in apoptosis is still unclear [24].  
 
 
Figure 2. Bcl-x pre-mRNA is spliced into two splice variants, Bcl-xL (at 
downstream 5’ splice site) and Bcl-xS (at upstream 5’ splice site) from Wilhelm et 
al. with modification [25] 
 
  In most cases, the splice variant ratio of Bcl-xL to Bcl-xS is observed to be 
shifted in favor of Bcl-xL, which subsequently showed increased expression levels of 
Bcl-xL in a number of cancers and cancer cell lines. Observations of Bcl-xS splice 
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variant increase and the induction of apoptosis of cancer cells also existed when the 5’-
splice sites of Bcl-xL were hindered with the treatment of antisense oligonucleotides 
[26]. There is also an indication of ceramide shifting the splice variant ratio in favor of 
Bcl-xS in human adenocarcinoma A549 cells [27]. The regulation and mechanism of 
Bcl-x alternative splicing is not clearly defined, but with the indication of ceramide 
having a potential role in this process an enzyme is postulated to be involved. That 
enzyme is thought to be iPLA2β, a calcium-independent phospholipase A2 enzyme 
which is observed in studies to cause apoptosis in β-cells using a novel mechanism 
involving ceramide generation [28][29][30]. 
 
 
 
 
 
 
 
 
 
 
 
 9 
  
 
 
Phospholipase A2 
 
 
 
Phospholipase A2 (PLA2) is a superfamily of enzymes involved in diverse lipid 
metabolism and disease progression [31][32][33]. In the late 19th century, the enzyme 
was first discovered as a major component of snake venom [32]. With the improvement 
of technology, researchers were able to purify different forms of PLA2s from an 
assortment of sources ranging from old world and new world snake venoms to human 
pancreatic enzymes. Depending on the disulfide bond patterns and structural motifs, 
scientists were able to divide and expand the different PLA2s into 15 distinct groups 
[32]. Furthermore, the groups were categorized into four types of PLA2s depending on 
their characteristics such as cytosolic cPLA2s, secreted sPLA2s, calcium-independent 
iPLA2s and platelet-activating factor acetylhydrolases [34]. Despite the diversity in 
structure and function, all the PLA2 enzymes are 40 to 99 percent identical in their 
amino acid sequences [35].  
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Figure 3. Phospholipase A2 targets the sn-2 position of membrane 
glycerophospholipids [36] 
 
PLA2s target the sn-2 position of membrane glycerophospholipids, the second 
carbon group of the glycerol backbone, to catalyze the release of free fatty acids such 
as arachidonic acid and lysophospholipids, which play vital roles in various biological 
activities [37]. For mammalians, the group of enzymes’ involvement can range from 
smooth muscle contraction to the biosynthesis of prostaglandins and leukotrienes, 
which plays an important role in signal transduction. In snake venom, the enzymes are 
toxic and are involved in the digestion and interference of normal physiological 
processes of their prey. Due to PLA2 enzymes having great diversity in biological roles, 
they are the one of the most studied group among the phospholipases [38].   
Group VI (GVI) PLA2 enzymes were categorized as Ca2+-independent PLA2s 
(iPLA2) due to their characteristics of not requiring calcium ions for catalytic activities 
unlike their related PLA2 enzymes [39]. The subgroup of iPLA2 enzymes, which are 
sn-2 
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classified into six distinct isoform groups, are the most recently described and the least 
well characterized subgroup of PLA2 enzymes [40]. Out of the six isoforms, GVIA was 
the first member of the iPLA2 family to be purified from macrophages in 1994 and is the 
best characterized iPLA2 enzyme [41].  
 Group VIA PLA2, also known as iPLA2β, has a mass of 85 to 88 kDA and contains 
a linker region, a catalytic domain with a lipase motif (GXSXG sequence) and 7 to 8 
ankyrin repeats [39][33], and is mainly found in the cytosol of resting cells [42]. Recent 
finding of iPLA2β’s ability to translocate to the membranes of the endoplasmic reticulum 
and mitochondria suggest that the enzyme also possesses a targeting sequence, which 
has not been identified yet [40]. This enzyme is suspected to be regulated through a 
variety of mechanisms involving ATP binding, caspase cleavage, calmodulin, and quite 
possibly by protein aggregation utilizing its ankyrin repeats [43].  
Possessing lysophospholipase activity along with transacylase activity, iPLA2β’s 
catalytic activities are carried out by the serine residue in the lipase motif at the active 
site [33]. Like its related PLA2 family members, iPLA2β cleaves the sn-2 position ester 
bond of membrane phospholipids, but exhibits no preference towards arachidonic acids 
in the sn-2 position [43]. The roles of iPLA2β are still to be defined, but with the recent 
generation of iPLA2β deficient mice allowing extensive research, recent studies 
including Dr. Barbour’s work has indication that iPLA2β has a role in phospholipid 
remodeling, the maintenance of phosphatidylcholine mass, and signal transduction 
[31][40][34]. Having roles in these physiological activities, studies suggest that iPLA2β 
can have diverse roles depending on different cell types, subsequently having important 
roles in apoptosis, bone formation, insulin secretion and sperm motility [43].  Few 
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studies also suggest the enzyme’s involvement in pathological conditions such as 
diabetes, Barth syndrome, ischemia and cancer [41].  
The correlation of iPLA2β and apoptosis first surfaced from Dr. Kenneth Polonsky’s 
group’s study [44]. The study indicated that in mouse insulinoma cell line MIN-6, ER 
stress induced by inhibiting sarcoendoplasmic reticulum Ca2+-ATPase (SERCA) 
triggered apoptosis due to the depletion of Ca2+ in the intracellular Ca2+ stores. The ER 
stress induced apoptosis was triggered independent of the change in the intracellular 
free Ca2+ concentration. However the trigger of apoptosis was dependent on a signal 
caused by the depletion of ER Ca2+ stores that utilized a lipoxygenase pathway of 
arachidonic acid generation, which implied that a PLA2 enzyme was involved [40][44]. A 
different study involving Fas-induced apoptosis of human leukemic U937 cells by Dr. 
Ichiro Kudo and colleagues [45] also implied the correlation of iPLA2β and apoptosis 
[40]. Reports from this study indicated that Fas-related arachidonic acid release related 
to Fas-induced apoptosis was dependent on iPLA2, and that the inhibition of iPLA2β 
delayed Fas-induced apoptosis while the inhibition of cPLA2 and sPLA2 had no effect 
[45].  
Recent studies with INS-1 cells by Dr. Ramanadham and colleagues 
[28][29][30][40] indicated a correlation of iPLA2β and apoptosis. In these studies, 
causing ER stress with thapsigargin was shown to promote the release of apoptogenic 
factors such as cytochrome c and Smac from the mitochondira, and the accumulation of 
these factors were observed to be amplified in iPLA2β-overexpressing cells [40]. The 
correlation of the accumulation of factors known to trigger the intrinsic apoptotic 
pathway and the expression levels of iPLA2β suggested that iPLA2β is likely to be 
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involved in the activation of the ER stress-induced apoptosis [40]. In these studies, the 
inhibition or knockdown of iPLA2β in β-cells reduced the induction of Neutral 
Sphingomyelinase-2 (NSMase2) which subsequently prevented ceramide accumulation. 
After observing a prevention of cytochrome c release following the inhibition of iPLA2β 
and NSMase2, ceramide generation which is induced by iPLA2β, was suggested to 
cause apoptosis in the INS-1 cells [28][29][30][40].  
In the study with A549 cells [27], ceramide was shown to promote apoptosis by 
shifting the alternative splicing of Bcl-x pre-mRNA in favor of Bcl-xS at the expense of 
decreasing the levels of Bcl-xL. This observation and the observation made in the 
previously mentioned study with INS-1 cells [28][29][30][40] prompted our lab to 
postulate that iPLA2β might be regulating apoptosis via regulating Bcl-xL with ceramide. 
In previous studies, our lab was able to obtain preliminary data from a study which the 
manuscript is submitted to support this postulation. INS-1 cells treated with thapsigargin 
to induce ER-stress exhibited significantly lower levels of Bcl-xL protein, and also 
showed a shift in alternative splicing towards Bcl-xS. Further investigation of ceramide’s 
effect on Bcl-x alternative splicing in INS-1 cells suggested that iPLA2β regulates Bcl-x 
splicing through both a ceramide dependent mechanism and a ceramide-independent 
mechanisms that utilizes the arachidonic acid or its metabolites. These observations 
further supported that iPLA2β regulates apoptosis in β-cells. 
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Figure 4. Airway resistance assay for iPLA2β-/- and wild type mice 
 
 After the investigations from our previous studies, our lab postulated that iPLA2β 
might be regulating apoptosis in mice lung with the similar mechanism observed in β-
cell. This hypothesis was postulated due to previous unpublished data [Fig 4] from Dr. 
Conrad’s and our lab’s study with iPLA2β-/- mice. An unexpected observation was made 
during an airway resistance assay in the experiment observing the effects of house dust 
mite induced asthma inflammation in the lungs of iPLA2β-/- and wild type mice. There 
was an observation of lung function compromise in the iPLA2β-/- mice compared to the 
wild type mice prior to the inhalation of methylcholine during the airway resistance 
assay [Fig 4]. The compromised lung function in iPLA2β-/- mice was thought to be 
secondary to altered lung architecture due to changes in remodeling, which is a process 
iPLA2 HDM
Methylcholine (mg/ml)
PBS 5 10 25 50
R
r s
0
2
4
6
8
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PLA2 KO
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dependent on apoptosis [47]. With indication of iPLA2β being involved in inducing 
apoptosis in β-cells as well as other cells [40], our lab speculated that the reduced 
apoptosis due to lack of iPLA2β is causing altered remodeling and architecture of the 
lung which subsequently compromises the lung function in our iPLA2β-/- mice.  
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Hypothesis 
 
 
 
 Based on the observation of lung function compromise in iPLA2β-/- mice from our 
lab’s previous studies, we hypothesize that GVIA Phospholipase A2 (iPLA2β) is involved 
in inducing apoptosis by regulating the expression of Bcl-xL in mice lung via alternative 
splicing. 
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Materials and Methods 
 
 
 
Animals and Tissue processing 
Our experimental protocol was performed in accordance with regulations of the 
Institutional Animal Care and Use Committee of Virginia Commonwealth University. 
Wild type C57BL/6 mice (n = 5) were received from The Jackson Laboratory (Bar 
Harbor, Maine), and the iPLA2β-/- mice (n = 4) were from the generated and maintained 
colony at Virginia Commonwealth University originating from Dr. John Turk’s lab at 
Washington University. The animal models used in this experiment were gender and 
age matched, and were fed ad libitum laboratory chow. With the help of Dr. Norbert F. 
Voelkel’s lab, one-half of the fresh lung tissue was snap frozen for protein and RNA 
analysis, and the other one-half was fixed by intratracheal infusion of 4% phosphate-
buffered formalin at a pressure of 23 cmH2O for histological examination.  
 
Identification of knockout mice 
For the identification of the knockout mice, genotyping of the alleles were done 
with the isolated genomic DNA of the mice tail. Tail tissue samples size of 0.5 cm from 
each mouse were used with the DirectPCR Lysis Reagent kit (Viagen Biotech). The 
samples used for the polymerase chain reaction (PCR) amplification were prepared in 
accordance to the manufacturer’s protocols. For the PCR analysis of the genomic DNA, 
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the 1400 bp wild type iPLA2β allele was assessed using a primer mix containing Neo 
primer (5’ TCG CCT TCT ATC GCC TTC TTG AC 3’) and wild type-antisense primer (5’ 
CTC CGC TTC TCG TCC CTC ATG GA 3’). The 400 bp knockout allele was assessed 
using primer mix containing the wild type sense primer (5’ AGC TTC AGG ATC TCA 
TGC CCA TC 3’) and MaEx-antisense primer (5’ GGG GCC TCA GAC TGG GAA TC 
3’). The prepared samples were put through 35 cycles of PCR amplification after being 
incubated at 95oC for 2 minutes for complete denaturing and activation of the DNA 
polymerase. Each cycle consisted of 30 seconds of denaturing of the template strands 
at 95oC, 30 seconds of annealing of the DNA primer at 56.5oC and 3 minute of 
elongation of the copy strands at 72oC. The PCR samples were separated and 
visualized by an agarose gel electrophoresis method. SYBR® Gold Nucleic Acid Gel 
Stain (Invitrogen) was used for the staining of the separated bands, and the bands at 
1400 bp and 400 bp were used to identify the wild type allele and knockout allele 
respectively.  
 
Preparation of the lung protein samples 
 Frozen lung tissues from each mouse were cut into a size of 0.5 cm with fresh 
razor blades. Each tissue samples were solubilized in separate test tubes filled with 
CelLyticTM MT buffer (Sigma-Aldrich) for 45 minutes on ice. Once the tissue was 
homogenized in the buffer, the homogenates were centrifuged at 1000 x g for 20 
minutes in a 4oC room. The retrieved protein samples were stored in a -80oC freezer. 
The protein concentration of each lung sample was obtained using a protein assay kit 
(Bio-Rad), and the sample protein size of 150 µg was assessed to be used for the 
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western blot analysis. Before the loading of the samples on to the SDS-PAGE gel, 150 
µg of each sample was added into 4X SDS-PAGE sample buffer and was denatured by 
heating the samples for 10 minutes at 95oC. 
 
Western blot analysis 
 The purified and reduced proteins were separated via sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). The reducing SDS-PAGE gel 
consisted of a 6% acrylamide stacking gel on top of a 10% acrylamide separating gel. 
The prepared proteins were separated against the KaleidoscopeTM (Bio-Rad) protein 
ladder in 1X Tris/Glycine/SDS Electrophoresis running gel buffer (Bio-Rad) consisting 
25 mM Tris-HCl, pH8.3, 200 mM glycine, 0.1% (w/v) SDS and water. The separated 
proteins on the SDS-PAGE gel were transferred via method of electroblotting onto 
nitrocellulose membrane. The protein transferred membrane was treated with a blocking 
buffer consisting of 5% diluted non-fat dry milk in Tris-buffered saline (TBS) 0.05% 
tween solution for 1 hour with gentle rocking at room temperature. The non-specific 
binding blocked membranes were immunoblotted with primary antibodies overnight in a 
4oC room followed by incubation of horseradish peroxidase (HRP) linked secondary 
antibodies for 1 hour at room temperature. Bcl-xL protein was probed with rabbit 
primary antibody (BD PharmingenTM) diluted to 1:1000 in 5% non-milk solution, and α-
tubulin protein was probed with mouse monoclonal IgM (Santa Cruz) diluted to 1:200 in 
5% non-milk solution. Bcl-xL was detected with HRP-conjugated Goat anti-rabbit 
(Pierce) antibody diluted to 1:5000, and α-tubulin was detected with HRP-conjugated 
rabbit anti-mouse IgM antibody (Pierce) diluted to 1:10,000. The immunoblotted proteins 
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were then visualized using the SuperSignal West Femto Chemiluminescent Substrate 
(PierceTM), and the band intensities were analyzed using ChemiDocTM XRS+ System 
(Bio-Rad) and Image LabTM software (Bio-Rad). 
 
RNA extraction, PCR and RNA analysis 
 TRIZOL® LS Reagent (Invitrogen) was used for RNA extraction from lung tissue 
samples. The protocol was done in accordance to the manufacturer’s instruction of 
homogenization of the tissue, phase separation of the homogenized samples, RNA 
precipitation and RNA washing. The obtained mRNA samples were quantified using a 
spectrophotometer instrument (NanoDrop) by getting the absorbance ratio of 260 
nm/280 nm. With the ratio’s being above 1.8 for every samples, the purity of each 
samples were accepted. The quantification of each sample determined the mRNA 
sample size of 0.08 µg to be used for the reverse transcriptase polymerase chain 
reaction (RT-PCR). The ThermoScriptTM Reverse Transcriptase kit (Invitrogen) was 
used for the RT-PCR to produce a cDNA of the obtained mRNA, and the protocol was 
carried out according to the manufacturer’s instructions. In the end, the non-specific 
endonuclease (RNase H) was added and incubated at 37oC for 20 minutes to remove 
RNA complementary to the cDNA. Bcl-x forward primer (5’ CCA GCT TCA CAT AAC 
CCC AG 3’) and Bcl-x reverse primer (5’ CCG TAG AGA TCC ACA AAA GTG TC 3’) 
were used for the RT-PCR. The samples of cDNA were then stored in a -80oC freezer. 
 The cDNA samples from each mouse were used for the PCR amplification for the 
quantification of Bcl-xL and Bcl-xS expression levels in each lung sample via 
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polyacrylamide gel electrophoresis. AccuPrimeTM Taq DNA Polymerase kit (Invitrogen) 
was used for the amplification of the cDNA in accordance to the manufacturer’s 
protocol. The prepared samples were put through 35 cycles of PCR amplification after 
being incubated at 94oC for 2 minutes for complete denaturing and activation of the 
DNA polymerase. Each cycle consisted of 30 seconds of denaturing of the template 
strands at 94oC, 30 seconds of annealing of the DNA primer at 54oC and 1 minute of 
elongation of the copy strands at 68oC. 
  SDS-PAGE method was utilized for the quantification of Bcl-xL and Bcl-xS 
expression levels. 8% polyacrylamide gel was used for the separation of 5 µL of the 
PCR products which was ran against a 100 bp DNA ladder (New England BioLabs) at 
110 volts in 0.5X Tris/Borate/EDTA (TBE) buffer solution. SYBR® Gold Nucleic Acid Gel 
Stain (Invitrogen) diluted in TBE solution was used for the staining of the separated 
bands, and the band intensities were analyzed using ChemiDocTM XRS+ System (Bio-
Rad) and Image LabTM software (Bio-Rad). 
 
Morphological assessment 
With the assistance of Dr. Voelkel’s lab, the lungs were fixed by intratracheal 
infusion of 4% phosphate-buffered formalin at a pressure of 23 cmH2O. The tissues 
were then sectioned at a thickness of 2 µm after being embedded in paraffin, and 
stained with hematoxylin and eosin. The lung sections were from 4 iPLA2β knockout 
mice and 4 wild type mice for morphological observation under light microscopy. Dr. 
Voelkel’s lab was gracious for granting access to their lab’s Axio Imager A1 (Zeiss) and 
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AxioVision (Zeiss) microscopy software for obtaining lung field images of the tissue 
sections.   
The Mean Linear Intercept (MLI) of the lung sections were obtained in reference 
to the method of Mizuno et al [48]. Ten random images of lung fields per tissue section 
were captured at magnification of X400. 2 diagonal lines connecting each corner of the 
lung field image were drawn using the ImageJ software to measure the line intercepts of 
septal wall of the lung. This process was done for every lung field image, and the 
number of Intercepts for the 2 diagonal lines were averaged for every individual lung 
tissue sections. The MLI of each lung tissue section was calculated by dividing the 
length of the diagonals by the mean septum intercept count. The length of the diagonal 
lines were measured by the ImageJ software.  
 
Statistical analysis 
 Results are expressed as means ± standard error. The numerical data were 
analyzed in a type 2 two tailed t-test in Microsoft Excel. It was determined that at p-
value less than 0.05 to be significant. 
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Results 
 
 
 
 
 
 
Figure 5. Genotyping of the alleles confirms the proper knockout of iPLA2β in the 
proposed knockout mice. Identification of the knockout and wild type mice was done 
from the genomic DNA’s from tail biopsies of the animal models. Genotyping was 
performed by PCR analysis, and the 1400 bp wild type allele was detected in 5 mice 
while the 400 bp knockout allele was detected in 4 mice. This control experiment 
allowed us to confirm and work with the proper animal models. (iPLA2β-/- mice, n = 4, 
control mice, n = 5) 
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a. 
 
 
b. 
 
Figure 6. Bcl-xL to tubulin ratios show that Bcl-xL protein levels are higher in the 
iPLA2β-/- mice than wild type mice. (a) 150 ug of protein from each mice lung sample 
was used for western blot analysis. (b) The ratios of Bcl-xL to tubulin protein from the 
western blot analysis represent the protein levels of Bcl-xL in the knockout and wild type 
mice. Protein analysis was the first step in finding a correlation of iPLA2β and Bcl-xL 
protein levels, and Bcl-xL protein levels were found to be higher in the iPLA2β-/- mice 
lung compared to the wild type mice lung. KO = iPLA2β-/- mice group, n = 3; WT = wild 
type mice group, n= 4. Values are expressed as the means ± standard error. *, p < 0.05 
(p-value = 0.036). 
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iPLA2β regulates the protein level of Bcl-xL in mice lung 
The protein levels of Bcl-xL in each mouse lung were quantified by western blot 
analysis utilizing SDS-PAGE separation and ELISA assay. The Bcl-xL expression levels 
are observed due to postulation of iPLA2β regulating Bcl-xL via alternative splicing. The 
postulation was prompted due to the observation made in previous studies with iPLA2β 
overexpressing INS-1 cells indicating the involvement of iPLA2β in β-cell apoptosis by 
inducing the generation of ceramide [28]. Ceramide having implication for lowering the 
ratio of Bcl-xL to Bcl-xS by affecting the alternative splicing of Bcl-x in A549 lung 
adenocarcinoma cells [27] prompted us to hypothesize that iPLA2β regulates Bcl-xL via 
alternative splicing pre-mRNA through a novel mechanism possibly utilizing ceramide in 
mice lung. In order to support this statement, it was essential for an initial measurement 
of Bcl-xL protein levels in the tissue. The Bcl-xL levels in the iPLA2β knockout and wild 
type mice were normalized to the levels of α-tubulin, a structural protein which protein 
levels should be consistent in all samples. 
Higher protein levels of Bcl-xL in the knockout mice compared to the wild type mice 
were observed which supports our hypothesis. The mean ratio of Bcl-xL to α-tubulin 
protein levels from the 3 knockout mice lung tissue was 0.691 ± 0.195, while the mean 
ratio of the 4 wild type mice were observed to be lower at 0.251 ± 0.208 [Fig 6b]. These 
ratios directly reflected the protein levels of Bcl-xL in the mice lung, and at the 0.05 level 
of significance, the data rejected the null hypothesis with a p-value of 0.036. This 
statistically significant data indicating a 3.3 times higher expression levels of Bcl-xL 
protein in the iPLA2β knockout mice lung compared to the wild type mice lung supported 
the first step of our hypothesis postulating that the presence of iPLA2β promotes 
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apoptosis by reducing the Bcl-xL protein levels. In the present study, we further 
investigate our hypothesis by looking at the alternative splicing of Bcl-x pre-mRNA and 
lung morphology to get a better idea of how iPLA2β is regulating Bcl-xL and to see if it is 
has a correlation to levels of apoptosis in the mice lung. 
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a. 
 
 
 
 
 
 
 
 
b. 
 
 
Figure 7. No significant difference in Bcl-x pre-mRNA alternative splicing were 
found in iPLA2β-/- and wild type mice lungs. (a) The mRNA of Bcl-xL and Bcl-xS 
expressed in the iPLA2β-/- and wild type mice were purified from each lung tissue 
samples, and their cDNA were amplified via PCR and separated via SDS-PAGE. (b) 
The quantification of the ratio of Bcl-xL to the Bcl-xS was to give a measurement of the 
shift in Bcl-x pre-mRNA alternative splicing. RNA analysis was used to observe 
correlation in the mice lung to the patterns observed in our lab’s unpublished work 
showing iPLA2β regulating Bcl-xL protein levels via alternative splicing in β-cells.  KO = 
iPLA2β-/- mice group, n = 3; WT = wild type mice group, n= 4. Values are expressed as 
the means ± standard error. (p-value = 0.41). 
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No significant evidence of iPLA2β regulating the alternative splicing of Bcl-x in mice lung 
Observation of the expression levels of Bcl-xL protein could only provide supporting 
evidence for iPLA2β regulating Bcl-xL protein expression, but could not provide 
evidence for the postulated mechanism of regulating via alternative splicing. Few 
studies indicated that a treatment with splice-switching oligonucleotides at the 5’ splice 
site of Bcl-xL pre-mRNA increases the splicing of the Bcl-xS isoform at the expense of 
reducing the levels of Bcl-xL mRNA [27][49]. Furthermore the previously mentioned 
study with A549 cells [27] demonstrated that ceramide can be responsible for this 
process. Indications of iPLA2β being involved in inducing ceramide generation via 
induction of NSMase2 in β-cells [28][29][30][40] draw a correlation of a possible 
involvement of iPLA2β in regulating Bcl-x pre-mRNA alternative splicing. This suggests 
the shifting of Bcl-xL alternative splicing to Bcl-xS to be a possible method of iPLA2β for 
regulating Bcl-xL protein levels in the mice lung. Therefore quantifying the mRNA levels 
of the two splice variants of Bcl-x in respect to each other was necessary for a clearer 
indication. The mRNA of Bcl-xL and Bcl-xS obtained from lung tissue samples were 
converted into cDNA and amplified through PCR. The PCR products were separated by 
polyacrylamide gel electrophoresis. The band intensities were quantified to assess the 
mRNA levels of Bcl-xL and Bcl-xS in each animal model lung tissue. The comparison of 
the ratios of Bcl-xL to Bcl-xS levels of the knockout mice to the wild type mice 
represented a measurement of the shift in alternative splicing of Bcl-x pre-mRNA.  
The knockout mice showed a ratio of 2.666 ± 0.882 compared to the wild type mice 
ratio of 2.160 ± 0.612 [Fig 7b], and at the significance level of 0.05 the data could not 
reject the null hypothesis with a p-value of 0.41. These results could not support our 
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hypothesis of a possible involvement of iPLA2β in regulating Bcl-x pre-mRNA alternative 
splicing, suggesting iPLA2β regulating Bcl-xL via a different mechanism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
  
 
       a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. H&E stained lung sections from iPLA2β knockout and wild type mice 
show no significant difference in lung morphology. Fixated tissues were embedded 
in paraffin then sectioned (2 um). The sections were stained with hematoxylin and 
eosin. Images shown are one of the 10 lung field of each animal model that best 
represents the animal model’s MLI. Original magnification, X400. 
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Figure 9. Quantification of the mean linear intercept of the lung sections from 
iPLA2β knockout and wild type mice show no significant difference in lung 
morphology. Lung septum walls were counted for the measurement of MLI in the lung, 
which gave an assessment for the average alveolar space sizes of the knockout and 
wild type mice. Alveolar space sizes were assessed to see if there was a difference in 
the lung morphology between the iPLA2β-/- and wild type mice lung. KO = iPLA2β-/- mice 
group, n = 4; WT = wild type mice group, n= 4. Values are expressed as the means ± 
standard error. (p-value = 0.093). 
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No strong evidence for iPLA2β involved in maintenance of mice lung morphology 
 Indication of iPLA2β regulating the expression of Bcl-xL protein from our western 
blot analysis lead to an investigation of iPLA2β’s effect on mice lung morphology. With a 
phenotypic observation of lung function compromise in iPLA2β-/- mice [Fig 4], we 
postulated a correlation of iPLA2β’s regulation of Bcl-xL to the maintenance of mice lung 
morphology. Lung function is suggested to be correlated to the maintenance of 
homeostasis and the structure of the lung [50][51], thus a possible alteration of structure 
in the knockout lung was postulated be observed.  
 Unexpectedly, a visual assessment provided no obvious observable 
morphological changes [Fig 8], therefore a quantitative assessment was necessary. As 
a preliminary assessment for any structural changes, a simple quantification of alveolar 
space sizes was adapted from Mizuno et al [48]. A widely used method of measuring 
the changes in alveolar sizes is assessing the MLI of two groups of lung samples 
[48][52][53][54]. MLI is a measurement of the mean distance between interalveolar 
septal walls, and could be utilized to assess the alveolar space sizes of the mice lungs 
[48]. The iPLA2β knockout lungs had an average MLI measurement of 33.786 ± 3.331 
and the wild type lungs had an average measurement of 38.243 ± 3.251 [Fig 9], which 
were not statistically significant. At a statistical significance of 0.05 could not be 
observed to reject the null hypothesis with a p-value of 0.093. 
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Discussion 
 
 
 
 
Figure 10. Model of hypothesized mechanism of iPLA2β regulating Bcl-xL levels 
 
The hypothesis postulated for this experiment was that iPLA2β subsequently 
regulates apoptosis in the mice lungs by regulating the expression levels of Bcl-xL via 
alternative splicing [Fig 10]. The hypothesis stemmed from an unexpected observation 
of compromised lung function in the iPLA2β knockout mice during a collaborative project 
of Dr. Barbour and Dr. Conrad [Fig 4]. The lung compromise was thought to be due to 
the changes in lung morphology of the iPLA2β knockout mice lung due to attenuated 
apoptosis in the lung cells. Furthermore, the correlation of iPLA2β and Bcl-x alternative 
splicing was postulated by our lab due to the observation made by Ramanadham et al 
including Dr. Barbour [28][29][30] of ER stress induced prolonged activation of iPLA2β in 
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INS-1 β-cells triggered mitochondrial abnormalities which subsequently caused 
apoptosis. The β-cell apoptosis is suggested to be carried out by iPLA2β’s induction of a 
novel mechanism involving sphingomyelin hydrolysis leading to ceramide generation 
[28]. The observation of β-cell apoptosis and the iPLA2β-dependent generation of 
ceramide is important in linking iPLA2β, Bcl-x splicing and apoptosis, because of the 
implication of ceramide causing a shift in alternative splicing of Bcl-x pre-mRNA in A549 
lung adenocarcinoma cells [27]. The treatment of ceramide eventually lead to an 
overexpression of Bcl-xS mRNA at the cost of reducing Bcl-xL mRNA subsequently 
increasing apoptosis in the A549 cells [27], which is a similar mechanism we are 
postulating iPLA2β to be utilizing in our animal models’ lung tissue to regulate Bcl-xL. 
The results obtained through this experiment displayed patterns indicating our 
hypothesis to be considered partially true. Our western blot analysis indicated an 
increase in Bcl-xL protein levels in the iPLA2β-/- mice lung compared to the wild type 
mice lung [Fig 6b], which implied iPLA2β’s involvement in down-regulating Bcl-xL. This 
was the most significant observation made in our experiment. In the previously 
mentioned study of ceramide-induced apoptosis with A549 cells [27], it was observed 
that the decreased levels of the splice variant Bcl-xL mRNA via ceramide treatment 
translated into decreased levels of Bcl-xL protein levels. Thus the decrease in levels of 
Bcl-xL protein observed in our iPLA2β-/- mice suggested that iPLA2β might be regulating 
Bcl-x alternative splicing via ceramide generation as we proposed. However, the results 
from our mRNA ratio analysis of Bcl-xL to Bcl-xS [Fig 7b] did not support the postulated 
mechanism for Bcl-xL regulation of our hypothesis. Our data from the MLI analysis [Fig 
9] also did not support our proposal of iPLA2β to be involved in the maintenance of mice 
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lung morphology which could have possibly indicated a correlation of iPLA2β and 
apoptosis regulation in mice lung.  
 
 
Figure 11. Alternative model of iPLA2β effecting Bcl-xL protein levels 
 
After rejecting the proposed mechanism of iPLA2β regulating Bcl-xL via 
alternative splicing, the lab postulated a different probable mechanism [Fig 11]. 
Observing the levels of the non-receptor tyrosine kinase c-Src could provide a better 
understanding of how iPLA2β regulates the Bcl-xL levels. Past studies [55][56][57][58] 
show iPLA2 to be involved in the regulation of Ca2+ influx by activating store operated 
Ca2+ channels (SOC) during Ca2+ store depletion in various cell types, including smooth 
muscle cells. It is a possibility that in the absence of iPLA2β, cells activate and 
upregulate different enzymes to respond to the depletion of intracellular Ca2+ stores. In 
a study with mouse embryo fibroblast [59] it was shown that Ca2+ influx induced by Ca2+ 
store depletion in Src- fibroblasts were significantly lower than the wild type fibroblasts. 
This suggests that c-Src could also be a possible downstream activator of SOCs during 
the depletion of internal Ca2+ stores. We postulate that c-Src could be upregulated in 
the absence of iPLA2β as an alternative to cause Ca2+ influx during the depletion of 
intracellular Ca2+ stores.  
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The c-Src kinase could be the link in explaining the increased levels of Bcl-xL 
protein in our iPLA2β-/- animal models. In a study with DHER14 and CSH12 cell lines 
[60], treating the cells with a Src family kinase inhibitor and repressing c-Src expression 
with Src antisense RNA down-regulated the Bcl-xL levels in addition to causing 
apoptosis. Similar to these observations, we propose that c-Src kinase could possibly 
be up-regulated and activated in our iPLA2β-/- mice lungs which is subsequently leading 
an increased protein level of Bcl-xL in our knockout mice lungs. There have been 
studies that demonstrated the importance of transcription factor families such as 
STATs, NF-kB, Ets families for the regulation of the BCL2L1 gene [61], the gene of Bcl-
x. In our case STAT-3, a possible downstream target protein of Src kinase [60], may be 
involved in regulating Bcl-xL levels [62]. In the next steps of investigating the possible 
mechanism of iPLA2β regulating Bcl-xL, our lab could compare the protein levels of 
pp60c-Src in the wild type and iPLA2β-/- mice lung. Confirming whether iPLA2β has an 
effect on c-Src kinase can have an implication of iPLA2β involving a JAK/STAT pathway 
to regulate the expression levels of Bcl-xL in the mice lung. 
 
 
Figure 12. Alternative model of iPLA2β regulating Bcl-xL protein levels utilizing 
ubiquitin-proteasome system 
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Another possible method of iPLA2β to be affecting the levels of Bcl-xL protein is 
by targeting the turnover rate of the protein [Fig 12]. Observation of a difference in Bcl-
xL protein levels without a shift in alternative splicing suggests that iPLA2β to be 
affecting the levels of Bcl-xL at the post translational stage of Bcl-xL. The ubiquitin-
proteasome system (UPS) is known to be involved in the regulation of wide variety of 
cellular processes by degrading variety of regulatory proteins [63][64][65][66]. Among 
the many cellular processes that UPS is involved, UPS is known to be involved in the 
degradation of proteins that regulate apoptosis [63][64][65]. Involvement of iPLA2β in 
UPS could be a possible mechanism in regulating the protein levels of Bcl-xL in mice 
lung. In muscle cells it is suggested that arachidonic acid metabolites are involved in 
inducing the expression of proteasomes and causing protein degradation [67]. 
Furthermore it is shown that inhibitors of PLA2 enzymes attenuate expressions of 
proteasome which suggests that PLA2 enzymes along with other enzymes are essential 
in inducing the ubiquitin proteasome system [67]. Arachidonic acid released by iPLA2β 
could possibly be targeting proteasomes to degrade Bcl-xL proteins to subsequently 
down-regulate Bcl-xL. The increased Bcl-xL protein levels observed in our knockout 
mice lungs could possibly be due to the decrease in degradation of Bcl-xL protein 
caused by the absence of iPLA2β. 
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Figure 13. Alternative model of iPLA2β affecting lung function in mice 
 
With our data suggesting no morphological changes to be observed in the 
iPLA2β-/- mice lung to explain the lung function compromise, we postulate that iPLA2β is 
affecting the lungs at the physiological levels rather than the morphological level [Fig 
13]. An experiment with iPLA2β-/- mice [68] suggested that iPLA2β plays an important 
role in agonist-induced constriction and dilation in vascular smooth muscles and 
endothelium by being involved in intracellular Ca2+ homeostasis. It was shown that 
basal state of vessels displayed no significant difference in diameters between the 
iPLA2β-/- and wild type mice, but iPLA2β-/- vessels displayed an increase sensitivity to 
phenylephrine induced constriction displaying smaller diameter at maximum constriction 
at a steady state while being insensitive to acetylcholine induced dilation [68]. This 
suggests that our iPLA2β-/- animal model might be experiencing lung function 
compromise due to the agonist-induced hypercontractility and attenuated endothelium-
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dependent relaxation in airway smooth muscles of the lung.  Hypercontractility and 
abnormalities in relaxation of airway smooth muscles have been associated with 
asthma [69] which causes lung function compromise in patients, and could be the case 
for our iPLA2β-/- mice. This could explain the reason for the iPLA2β-/- house dust mite 
mice model experiencing lung function compromise compared to the wild type even 
before the treatment with the lung airway constricting methylcholine during the airway 
resistance assay [Fig 4] of our previous study. This postulation is further supported by 
the observation of the exacerbated difference in airway resistance between the iPLA2β-/- 
and wild type mice after the treatment of methylcholine. In order to assess the possibility 
of abnormalities in relaxation of the iPLA2β-/- airway smooth muscles, further 
investigation of vasopressin or nitric oxide (NO) production in the mice lung is 
necessary. In studies [70][71] NO is found to induce relaxation in airway smooth muscle 
cells, and looking into phosphorylation of NO synthases (NOS) can be a good indication 
of a possible malfunction in NO production in the endothelium cells associated with 
airway smooth muscle cells causing insensitivity to agonist-induced relaxation just as it 
was proposed in the study with vessels of iPLA2β-/- mice [68]. In the study with iPLA2β-/- 
vessels [68] they observed an inhibition of NO production and endothelial NOS (eNOS) 
phosphorylation by an iPLA2 inhibitor. Western blot analysis of phospho-eNOS at 
Ser1177 was used in their study [68], and a similar analysis in our animal model lungs 
can give us an indication of any attenuated NO production levels to cause lung function 
compromise in an iPLA2β knockout condition. 
There is a possibility that our data was underestimating iPLA2β’s effect on Bcl-x 
pre-mRNA alternative splicing due to a broad sample pool of mRNA which was taken 
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from the lung tissue as a whole. Since we are postulating that iPLA2β is possibly 
involved in the functionality of airway smooth muscles and endothelial cells, it will be 
worth repeating the mRNA quantification of Bcl-x isoforms with these specific lung cells. 
The quantification with the specific lung cells relevant to lung functionality and 
investigating c-Src kinase activity could clarify the mechanism of Bcl-xL regulation and 
possibly pave pathways to further our current study. 
In summary, our data from the present study suggest that iPLA2β regulates 
protein levels of Bcl-xL in mice lung, and the data further confirms that iPLA2β regulating 
alternative splicing of Bcl-x via ceramide is possibly a β-cell specific mechanism that is 
not found be true in mice lung tissue. Although there was no evidence in our data of 
iPLA2β regulating alternative splicing of Bcl-x pre-mRNA in mice lung as a whole, further 
investigation is needed to discern if it is also the case for specific cells and tissue within 
the lung such as airway smooth muscle and endothelial cells. Understanding the 
mechanism utilized by iPLA2β in regulating Bcl-xL in cells and tissue that is relevant to 
lung function, and iPLA2β’s effects on the physiology of the mice lung could possibly 
lead to therapeutic targets for asthma and lung function compromise related diseases. 
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